News on research and diagnostics for metabolic disorders and metabolic diseases.
The Finnish biotechnology firm also announced plans to raise up to €80 million in the coming year.
The firm is conducting clinical trials in preparation for applying for FDA clearance to market its POC instrument and first assay in the first quarter of next year.
The firm said it anticipates launching the platform in Europe next year and completing its first round of external financing in the first quarter of 2020.
The FDA cleared the system, comprising a blood collection device and associated test to measure long-term glucose levels in patients with diabetes.
The test combines a genetic risk analysis with behavioral and lifestyle assessments, and uses Thermo Fisher Scientific's TaqMan OpenArray for genotyping.
